首页> 外文OA文献 >A DOUBLE-BLIND COMPARISON OF THE EFFICACY OF FOSFOMYCIN AND CARBENICILLIN INDANYL IN COMPLICATED URINARY TRACT INFECTIONS
【2h】

A DOUBLE-BLIND COMPARISON OF THE EFFICACY OF FOSFOMYCIN AND CARBENICILLIN INDANYL IN COMPLICATED URINARY TRACT INFECTIONS

机译:福莫霉素和羧苄青霉素茚满在复杂尿路感染中的双盲比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Comparative double blind trial of fosfomycin calcium (FOM) and carbenicillin indanyl sodium (I-CBPC) was performed in 72 patients of complicated urinary tract infection with Pseudomonas or Proteus species. Patients were treated orally for a week at a daily dose of 2 g of FOM or I-CBPC. The results obtained were summarized as follows: 1. The background characteristics of two groups were statistically analyzed, and they were to be satisfied in their uniformity as the subject of this trial. 2. The degree of improvement of symptoms and urinary findings, and the change of bacterial count and species in urine were also compared and were not significantly different between the two groups. 3. The clinical effects were excellent in 4 cases, good in 7 cases, fair in 15 cases, and poor in 11 cases out of 37 cases of the FOM group, and excellent in 4 cases, good in 12 cases, fair in 11 cases, and poor in 8 cases out of 35 cases of the I-CBPC group. No significant difference was obtained between the two groups. 4. The incidence of adverse reactions was 2 out of 41 cases of the FOM group (4.9%) and lout of 43 cases of the I-CBPC group (2.3%), showing no significant difference. Considering the data described above, there was no significant difference between FOM and 1-CBPC groups on overall clinical efficacy, utility, improvement of symptoms and findings, and incidence of adverse reactions.
机译:磷霉素钙(FOM)和羧苄青霉素茚满钠(I-CBPC)的比较双盲试验在72例患有假单胞菌或变形杆菌的复杂尿路感染患者中进行。患者每天口服2 g FOM或I-CBPC口服治疗。获得的结果归纳如下:1.对两组的背景特征进行统计学分析,并以其均匀性作为本试验的对象满意。 2.比较了症状和尿液发现的改善程度,以及尿液中细菌数量和种类的变化,两组之间无显着差异。 3. FOM组37例中,优4例,良7例,良15例,差11例,良4例,良12例,良11例。 I-CBPC组中的35例中有8例为贫困。两组之间没有显着差异。 4.不良反应发生率为FOM组41例中的2例(4.9%),I-CBPC组43例中的不良反应(2.3%),差异无统计学意义。考虑到上述数据,FOM组和1-CBPC组在总体临床疗效,效用,症状和发现的改善以及不良反应的发生率方面无显着差异。

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号